Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Researchers study how human herpes virus packages genetic information during infection

An international collaboration of researchers including Felicia Goodrum of the University of Arizona's immunobiology department has studied how a human herpes virus carried by the majority of the population packages its genetic information during infection.

31 Jul 2013

Emergency physicians correctly identify nearly 100% of patients with Bell's palsy

Emergency physicians correctly identified nearly 100 percent of patients with Bell's palsy, the symptoms of which are nearly identical to potentially life-threatening diseases such as stroke and brain tumors.

26 Jul 2013

Discovery of pressure-driven infection mechanism opens door to new treatments for viral infections

The virus that causes those painful lip blisters known as cold sores has an internal pressure eight times higher than a car tire, and uses it to literally blast its infectious DNA into human cells, scientists are reporting in a new study.

25 Jul 2013

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer Inc. announced today that tofacitinib has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies in several additional countries around the world, including Switzerland, which is the first European country to receive approval.

15 Jul 2013

Study: Popular search engines share search data about medical conditions with third parties

Researchers find that popular websites share search data with advertisers and other third parties. The National Security Agency is tracking your phone calls. And online snoops may be keeping tabs on your Internet health searches, too.

10 Jul 2013

ERC awards grants to boost research on vaccines

Vaccination has achieved huge success in controlling many devastating infectious diseases. However, there are still many such diseases, or 'pathogens', against which we cannot generate life-long protective immunity.

9 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Researchers discover promising new way to treat HIV-related blood cancer

Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

26 Jun 2013

Research shows other viruses also play a role in AIDS transmission

While antiretroviral drugs offer an efficient means of preventing the replication of HIV in the blood, shedding of HIV may occur in semen, so that other persons can become infected during unprotected sexual intercourse.

24 Jun 2013

Hebrew University student develops drug formulations to treat illnesses through skin applications

New, more efficient drug formulations designed to treat illnesses through skin applications -- thus avoiding serious side effects associated with oral drug-taking -- have been developed by a student at the Hebrew University of Jerusalem.

12 Jun 2013

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity.

11 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

HSV-1 exploits immune system receptor to boost infectivity and cause disease

Researchers at the University of California, San Diego School of Medicine and colleagues report that the herpes simplex virus type-1 (HSV-1), which affects an estimated 50 to 80 percent of all American adults, exploits an immune system receptor to boost its infectivity and ability to cause disease.

7 Jun 2013

New plug-in optical sensor can help diagnose Kaposi's sarcoma

As antiretroviral drugs that treat HIV have become more commonplace, the incidence of Kaposi's sarcoma, a type of cancer linked to AIDS, has decreased in the United States.

5 Jun 2013

Twitter: A popular source for receiving and sharing new information about vaccines

Twitter is a popular source for receiving and sharing new information about vaccines, and also a basically reliable one, according to a study published in the June issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

BioAlliance Pharma SA, a Company dedicated to the development of orphan oncology products and supportive care products, has presented the results of the pharmacokinetic and pharmacodynamic study on Sitavig at the 10th EADV spring symposium (European Academy of Dermatology and Venereology) in Cracow (Poland) on May 24, 2013.

28 May 2013

UIC's Center for Clinical and Translational Science selects six research projects for new pilot grants

The University of Illinois at Chicago's Center for Clinical and Translational Science has selected six research projects to receive pilot grants in 2013.

15 May 2013